<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295304</url>
  </required_header>
  <id_info>
    <org_study_id>NR-DOC-14670</org_study_id>
    <nct_id>NCT04295304</nct_id>
  </id_info>
  <brief_title>NR600 System Retinal Prosthesis for Patients With Retinal Degenerative Diseases</brief_title>
  <acronym>NR</acronym>
  <official_title>Safety and Performance Evaluation of the NR600 System in Subjects With End-stage Inherited Outer Retinal Degenerative Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nano Retina</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nano Retina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to demonstrate safety of the NR 600 System, and to evaluate the&#xD;
      performance of the device in restoring visual activity of daily living in subjects with&#xD;
      retinal degenerative diseases and severe visual impairment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NR600 is a retinal prosthetic system intended to provide electrical stimulation to the&#xD;
      retina to induce visual perception in patients with severe to profound vision loss due to&#xD;
      degenerative retinal disease. The system is consisting of an autonomous epiretinal implant&#xD;
      with penetrating electrodes, Glasses and a Clinician Station. The implant is Infrared (IR)&#xD;
      powered and is designed to convert visual input into well-defined electrical stimulation&#xD;
      patterns suited to elicit neuronal retina activity. All study subjects will be implanted with&#xD;
      the device in one eye and will be followed for 18-months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>within 9 months post implantation</time_frame>
    <description>Occurrence of serious adverse events related to the device and/or to the procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Retinal Degeneration</condition>
  <arm_group>
    <arm_group_label>NR600 device implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retinal surgery and implantation of epi-retinal prosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Retinal surgery with implantation of epi-retinal device</intervention_name>
    <description>Retinal surgery and implantation of epi-retinal prosthesis</description>
    <arm_group_label>NR600 device implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have confirmed diagnosis of end-stage hereditary outer retinal degeneration such as RP&#xD;
             or cone-rod dystrophy&#xD;
&#xD;
          -  Visual acuity in both eyes from light perception to no light perception&#xD;
&#xD;
          -  Confirmed functional ganglion cells and optic nerve in the implanted eye&#xD;
&#xD;
          -  History of useful vision&#xD;
&#xD;
          -  Mentally competent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diseases or condition that affect retinal and or optic nerve function&#xD;
&#xD;
          -  Optic Nerve diseases&#xD;
&#xD;
          -  Diseases or conditions that, in the judgement of the surgeon, impede the ability to&#xD;
             implant the device or would prevent the system from functioning&#xD;
&#xD;
          -  Dry eye&#xD;
&#xD;
          -  Pre-disposition to eye rubbing&#xD;
&#xD;
          -  Posterior pole severe staphyloma&#xD;
&#xD;
          -  Strabismus superior to 10 prismatic diopter&#xD;
&#xD;
          -  Severe nystagmus&#xD;
&#xD;
          -  Corneal endothelium density &lt; 1500 cells/mm2&#xD;
&#xD;
          -  Refractive error ≥±8 diopters spheric and 3.5 diopter cylindric&#xD;
&#xD;
          -  Currently pregnant (female subject) or inadequate contraceptive treatment in female&#xD;
             subjects &lt;50 years of age.&#xD;
&#xD;
          -  Hyperthyroidism or hypersensitivity to iodine&#xD;
&#xD;
          -  Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression)&#xD;
&#xD;
          -  Participation in another study with any investigational drug or device that may&#xD;
             conflict with the objectives, follow-up or testing of this study&#xD;
&#xD;
          -  Conditions likely to limit life to less than 1 year from time of recruitment to the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weinberger Dov, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Retinal surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rigler</last_name>
    <phone>+972747377640</phone>
    <email>dudur@nano-retina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inge Joniau, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Vriens</last_name>
      <phone>+ 32 16 34 22 29</phone>
      <email>ingeborg.vriens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Peter Stalmans, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila</last_name>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rita Ehrlich, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel AViv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadar Orlovik</last_name>
      <email>hadaro@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Adiel Barak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shulamit Schwartz, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Calcagno, Dr.</last_name>
      <phone>+39 0226436212</phone>
      <email>calcagno.francesca@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Bandello, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico A. Gemelli, IRCCS</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falsini Benedetto, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Stanislao Rizzo, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benedetto Falsini, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

